Voice-related quality of life in adults with neurofibromatosis type 1.

[1]  G. Mortier,et al.  Voice characteristics in adults with neurofibromatosis type 1. , 2011, Journal of voice : official journal of the Voice Foundation.

[2]  G. Mortier,et al.  Speech disorders in neurofibromatosis type 1: a sample survey. , 2010, International journal of language & communication disorders.

[3]  T. Pring,et al.  Self-perception of speech changes in patients with Parkinson's disease following deep brain stimulation of the subthalamic nucleus , 2010, International journal of speech-language pathology.

[4]  S. Huson,et al.  Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register service , 2010, American journal of medical genetics. Part A.

[5]  K. Chapman,et al.  Speech–language characteristics of children with neurofibromatosis type 1 , 2010, American journal of medical genetics. Part A.

[6]  O. Aaltonen,et al.  Speech characteristics in neurofibromatosis type 1 , 2010, American journal of medical genetics. Part A.

[7]  A. Schindler,et al.  Correlation Between the Voice Handicap Index and Voice Measurements in Four Groups of Patients with Dysphonia , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[8]  B. Korf,et al.  Neurofibromatosis type 1. , 2009, Journal of the American Academy of Dermatology.

[9]  F. Dikkers,et al.  A retrospective study concerning the psychosocial impact of voice disorders: Voice Handicap Index change in patients with benign voice disorders after treatment (measured with the Dutch version of the VHI). , 2009, Journal of voice : official journal of the Voice Foundation.

[10]  D. Taruscio,et al.  Health-Related Quality of Life in Patients with Neurofibromatosis Type 1 , 2008, Dermatology.

[11]  V. Woisard,et al.  Validation of the Voice Handicap Index by Assessing Equivalence of European Translations , 2008, Folia Phoniatrica et Logopaedica.

[12]  P. Boon,et al.  The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease , 2007, Clinical Neurology and Neurosurgery.

[13]  D. Kuik,et al.  Voice in early glottic cancer compared to benign voice pathology , 2007, European Archives of Oto-Rhino-Laryngology.

[14]  D. Stephenson,et al.  Recent developments in neurofibromatosis type 1 , 2007, Current opinion in neurology.

[15]  R. Ferner.  Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective , 2007, The Lancet Neurology.

[16]  G. Page,et al.  Impact of neurofibromatosis 1 on Quality of Life: A cross‐sectional study of 176 American cases , 2006, American journal of medical genetics. Part A.

[17]  C. Lançon,et al.  Neurofibromatose de type 1: Troubles psychiatriques et altération de la qualité de vie , 2006 .

[18]  A. Leplège,et al.  Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. , 2001, Archives of dermatology.

[19]  G Molenberghs,et al.  The dysphonia severity index: an objective measure of vocal quality based on a multiparameter approach. , 2000, Journal of speech, language, and hearing research : JSLHR.

[20]  K. North.  Neurofibromatosis type 1. , 2000, American journal of medical genetics.

[21]  M. Zöller,et al.  A psychiatric 12-year follow-up of adult patients with neurofibromatosis type 1. , 1999, Journal of psychiatric research.

[22]  I. Cobeta,et al.  Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs. , 1997, Journal of voice : official journal of the Voice Foundation.

[23]  C. Newman,et al.  The Voice Handicap Index (VHI)Development and Validation , 1997 .

[24]  R. Heim,et al.  Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. , 1995, Human molecular genetics.

[25]  K. North.  Neurofibromatosis Type 1: Review of the First 200 Patients in an Australian Clinic , 1993, Journal of child neurology.

[26]  V. Riccardi.  Neurofibromatosis: Phenotype, Natural History and Pathogenesis , 1993 .

[27]  M. Daston,et al.  The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes , 1992, Neuron.

[28]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.

[29]  P. O'Connell,et al.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.

[30]  P. O'Connell,et al.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.

[31]  Allan E. Rubenstein,et al.  Neurofibromatosis: A Handbook for Patients, Families, and Health Care Professionals , 1990 .

[32]  P. Schauer,et al.  Head and neck manifestations of neurofibromatosis , 1986, The Laryngoscope.

[33]  V. M. Riccardi,et al.  Von Recklinghausen neurofibromatosis. , 1981, The New England journal of medicine.

[34]  James T. Elder,et al.  Retrospective analysis of patients attending a neurofibromatosis type 1 clinic , 2007, Journal of paediatrics and child health.

[35]  B. Moore,et al.  Behavioral phenotype of neurofibromatosis, type 1. , 2000, Mental retardation and developmental disabilities research reviews.

[36]  W Seidner,et al.  Recommendation by the Union of European Phoniatricians (UEP): standardizing voice area measurement/phonetography. , 1983, Folia phoniatrica.